Do you need pharmacovigilance before your Phase 1 IND?

The short answer is yes — and the clock starts earlier than most founders realise. By the time you file your IND and the 30-day FDA review window opens, you should already have a documented safety system, a named safety contact, and processes in place to handle adverse events from your first human subject.

This surprises a lot of early-stage teams. Pharmacovigilance is typically associated with post-marketing surveillance — drug companies tracking spontaneous reports after approval. But the FDA's IND safety reporting obligations under 21 CFR Part 312 apply from the moment you begin investigating your drug in humans, not after you receive approval.

What the FDA actually requires at IND stage

Your IND must include a description of your pharmacovigilance system — specifically, how you will collect, assess, and report adverse events during the trial. Under 21 CFR 312.32, sponsors are required to submit IND safety reports for:

• 7-day reports — for any fatal or life-threatening unexpected serious adverse drug reaction (suspected to be related to the investigational product)
• 15-day reports — for all other unexpected serious suspected adverse reactions (SUSARs) that are serious but not immediately fatal or life-threatening
• Annual reports — a Development Safety Update Report (DSUR) summarising all SUSARs and the overall safety profile of the investigational product over the preceding year

These are not optional. Failure to submit a 7-day report on time — from the moment the sponsor first becomes aware of the event — is a reportable GCP deficiency and can trigger a clinical hold.

What "a functioning PV system" looks like at Phase 1

You don't need a fully staffed safety department with a validated safety database to file your first IND. But you do need several things to be in place and documented:

1. A named safety contact (sponsor medical officer)

The IND must identify a qualified individual responsible for evaluating adverse events and making reportability determinations. At early stage, this is typically a Chief Medical Officer, a contracted medical monitor, or a fractional VP Pharmacovigilance. This person must be reachable 24/7 during active trial conduct — investigators need to be able to escalate SAEs in real time.

2. A current Investigator's Brochure

The IB is your reference safety information for the clinical programme. It summarises all preclinical toxicology and any prior clinical safety data, and defines which adverse reactions are "listed" (expected). Every expectedness assessment for SUSAR classification is made against the IB — so if your IB is incomplete or inaccurate, your reportability determinations will be wrong.

The IB must be updated at least annually (and immediately if significant new safety information emerges), which is itself a pharmacovigilance activity.

3. Written safety reporting procedures (SOPs)

The FDA expects sponsors to have written standard operating procedures governing how adverse events are collected from investigators, assessed for seriousness and causality, classified as SUSARs or non-SUSARs, and submitted to the FDA and to other regulatory authorities holding corresponding CTAs. These don't need to be elaborate — two or three well-written SOPs are sufficient for a single-IND Phase 1 programme.

4. A mechanism for tracking cases

You need to be able to demonstrate that you have received, assessed, and reported every SUSAR within the required timelines. For a small programme this can be as simple as a structured spreadsheet with case receipt dates, assessment dates, and submission timestamps — but the audit trail must exist. If the FDA inspects your IND, they will ask for a line listing of all IND safety reports submitted to date and will cross-reference those against the investigator site records.

5. Investigator notification

Under 21 CFR 312.32(c)(1)(ii), sponsors must notify all participating investigators of any SUSAR that was submitted to the FDA. This requirement is often overlooked by small sponsors who are running a single-site trial and assume direct communication is sufficient. The notification must be written and distributable — typically a "Dear Investigator" letter or a safety update to the IB.

What happens if you don't have these in place

The FDA's clinical trial oversight model is largely trust-based — they do not inspect every IND before the 30-day review window expires. However, if you receive a clinical hold, undergo a directed inspection, or an SAE occurs at your trial site, the absence of documented safety procedures is immediately visible.

Do you need a QPPV for an IND?

No — the QPPV is a European requirement for Marketing Authorisation Holders (MAHs) under GVP Module I. If you are operating under a US IND only, there is no statutory requirement for a QPPV. However, if you hold or intend to hold a Clinical Trial Authorisation (CTA) in the EU/EEA, you will need a named safety contact for the EU regulatory authorities — and if your programme advances to an MAA, you will need a qualified QPPV in the EU/EEA who can be inspected.

Many early-stage biotechs operating dual US/EU programmes designate a single person to serve as both the US medical officer and the EU safety contact. This works well in practice if the person is qualified and the programme is small.

The IND safety obligations are manageable if you start early

None of this needs to be expensive or operationally complex for a Phase 1 programme. The key is not to wait until you're six months into your first trial and the site coordinator calls with a serious adverse event and there's no documented process for what happens next.

A fractional pharmacovigilance resource — a part-time VP Drug Safety or medical monitor — can put the necessary infrastructure in place in two to four weeks, typically at a fraction of the cost of a full-time hire. For most small biotechs, you need:

• An up-to-date Investigator's Brochure reviewed for safety content
• Two or three SOPs covering ICSR intake, causality/expectedness assessment, and regulatory reporting
• A case tracking system (even a simple spreadsheet) with an audit trail
• A named safety contact available 24/7 during trial conduct
• Investigator notification procedures and templates

That's your Phase 1 PV system. It's not glamorous, but it's what the FDA is looking for — and it's what protects you from a clinical hold or an inspection finding if something goes wrong.